Back to News
Market Impact: 0.28
Galderma Reports Three-Year Nemluvio Data In Moderate-to-Severe Atopic Dermatitis
Source: Nasdaq
Healthcare & Biotech
Galderma reported new three-year ARCADIA long-term extension data showing Nemluvio (nemolizumab) delivered sustained improvements in patients with moderate-to-severe atopic dermatitis. The positive durability data supports Nemluvio's clinical profile and its commercial opportunity in chronic inflammatory skin disease.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.42
Ticker Sentiment
GALD0.68
More News
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Walgreens owner nears $9 billion deal to sell Boots chain- WSJ
- Why is Toho stock volatile today?
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Some Oura IPO Investors Were Said to Push Back Citing Valuation
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: New Reporting Features, UI Improvements, and Chat Optimizations
- Selecting an AI Research Platform for Institutional Investors